Loading…
Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network
Safety of dupilumab in atopic dermatitis (AD) was investigated in randomized controlled trials (RCT). However, head-to-head trials comparing with conventional systemic drugs are lacking and large real-world data on the long-term safety profile as compared are scarce. To compare long-term safety prof...
Saved in:
| Published in: | The Journal of dermatological treatment 2024-12, Vol.35 (1), p.2421429 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c300t-385d95d1071924330d901e747c4df123f346773039321a451e88e35758c816083 |
| container_end_page | |
| container_issue | 1 |
| container_start_page | 2421429 |
| container_title | The Journal of dermatological treatment |
| container_volume | 35 |
| creator | Zirpel, Henner Ludwig, Ralf J Olbrich, Henning Kridin, Khalaf Ständer, Sascha Thaçi, Diamant |
| description | Safety of dupilumab in atopic dermatitis (AD) was investigated in randomized controlled trials (RCT). However, head-to-head trials comparing with conventional systemic drugs are lacking and large real-world data on the long-term safety profile as compared are scarce.
To compare long-term safety profile of dupilumab with conventional systemic drugs used in the management of moderate to severe AD.
Data from electronic health records of AD patients treated with either dupilumab, azathioprine, Cyclosporine A, mycophenolate mofetil, methotrexate, or oral glucocorticoids were retrieved from the TriNetX
. Risks of adverse events and new onset of type-2-inflammatory diseases within 5 years after treatment initiation was investigated.
5 propensity-matched cohorts, up to 18,708 individuals per cohort, were created. Dupilumab treatment displayed reduced risk for diseases of the circulatory, the upper respiratory, and the musculoskeletal system, infections, and type 2 diseases as compared to all other treatment options. In contrast risk for conjunctivitis was increased in dupilumab treated patients as compared to mycophenolate mofetil and methotrexate.
Here presented data indicates that treatment with dupilumab for AD has reduced risk for adverse effects of conventional systemic drugs and thus might be safer. Obtained data should be verified in prospective studies. |
| doi_str_mv | 10.1080/09546634.2024.2421429 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cd4d5731e7be4858a0f0ed66af78e90a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cd4d5731e7be4858a0f0ed66af78e90a</doaj_id><sourcerecordid>3123801739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-385d95d1071924330d901e747c4df123f346773039321a451e88e35758c816083</originalsourceid><addsrcrecordid>eNo9UU1v1DAQtRCILgs_AeQjl5RxbMcON7Tio1IlDtCz5Y3H1CWJg-1Q7Z_ht-LtbnvxWG_eezOaR8hbBpcMNHyAXoqu4-KyhbY-omWi7Z-RDROKNUxJ_pxsjpzmSLogr3K-A2C8A_2SXPBe6F5CtyH_dnFabAo5zjR6mq3HcqBLij6MSMNMF1sCziXT-1BuqS1xCQN1mKaKl5BpSWgLulPbrUsY18nuaUx0iPPfqgxxtiPNh1xwqtIH_lTxj7T-Rnof0-ios8VSn-JEyy3Smx90xlI7v1-TF96OGd-c65bcfPn8c_etuf7-9Wr36boZOEBpuJaul46BYn0rOAfXA0Ml1CCcZy33XHRKceA9b5kVkqHWyKWSetCsnoRvydXJ10V7Z5YUJpsOJtpgHoCYfhmbShhGNIMTTipe7fcotNQWPKDrOuuVxh5s9Xp_8qpX_LNiLmYKecBxtDPGNRteF9LAVF1mS-SJOqSYc0L_NJqBOcZsHmM2x5jNOeaqe3cese4ndE-qx1z5fy93pFI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3123801739</pqid></control><display><type>article</type><title>Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Zirpel, Henner ; Ludwig, Ralf J ; Olbrich, Henning ; Kridin, Khalaf ; Ständer, Sascha ; Thaçi, Diamant</creator><creatorcontrib>Zirpel, Henner ; Ludwig, Ralf J ; Olbrich, Henning ; Kridin, Khalaf ; Ständer, Sascha ; Thaçi, Diamant</creatorcontrib><description>Safety of dupilumab in atopic dermatitis (AD) was investigated in randomized controlled trials (RCT). However, head-to-head trials comparing with conventional systemic drugs are lacking and large real-world data on the long-term safety profile as compared are scarce.
To compare long-term safety profile of dupilumab with conventional systemic drugs used in the management of moderate to severe AD.
Data from electronic health records of AD patients treated with either dupilumab, azathioprine, Cyclosporine A, mycophenolate mofetil, methotrexate, or oral glucocorticoids were retrieved from the TriNetX
. Risks of adverse events and new onset of type-2-inflammatory diseases within 5 years after treatment initiation was investigated.
5 propensity-matched cohorts, up to 18,708 individuals per cohort, were created. Dupilumab treatment displayed reduced risk for diseases of the circulatory, the upper respiratory, and the musculoskeletal system, infections, and type 2 diseases as compared to all other treatment options. In contrast risk for conjunctivitis was increased in dupilumab treated patients as compared to mycophenolate mofetil and methotrexate.
Here presented data indicates that treatment with dupilumab for AD has reduced risk for adverse effects of conventional systemic drugs and thus might be safer. Obtained data should be verified in prospective studies.</description><identifier>ISSN: 0954-6634</identifier><identifier>ISSN: 1471-1753</identifier><identifier>EISSN: 1471-1753</identifier><identifier>DOI: 10.1080/09546634.2024.2421429</identifier><identifier>PMID: 39489506</identifier><language>eng</language><publisher>England: Taylor & Francis Group</publisher><subject>Adolescent ; Adult ; Antibodies, Monoclonal, Humanized - adverse effects ; Atopic dermatitis ; Azathioprine - adverse effects ; Azathioprine - therapeutic use ; comorbidities ; conventional systemic therapy ; Cyclosporine - adverse effects ; Cyclosporine - therapeutic use ; Dermatitis, Atopic - drug therapy ; Dermatologic Agents - adverse effects ; Dermatologic Agents - therapeutic use ; dupilumab ; Female ; Glucocorticoids - administration & dosage ; Glucocorticoids - adverse effects ; Glucocorticoids - therapeutic use ; Humans ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; Male ; Methotrexate - adverse effects ; Methotrexate - therapeutic use ; Middle Aged ; Mycophenolic Acid - adverse effects ; risk ; safety ; Severity of Illness Index ; Treatment Outcome ; United States ; Young Adult</subject><ispartof>The Journal of dermatological treatment, 2024-12, Vol.35 (1), p.2421429</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-385d95d1071924330d901e747c4df123f346773039321a451e88e35758c816083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39489506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zirpel, Henner</creatorcontrib><creatorcontrib>Ludwig, Ralf J</creatorcontrib><creatorcontrib>Olbrich, Henning</creatorcontrib><creatorcontrib>Kridin, Khalaf</creatorcontrib><creatorcontrib>Ständer, Sascha</creatorcontrib><creatorcontrib>Thaçi, Diamant</creatorcontrib><title>Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network</title><title>The Journal of dermatological treatment</title><addtitle>J Dermatolog Treat</addtitle><description>Safety of dupilumab in atopic dermatitis (AD) was investigated in randomized controlled trials (RCT). However, head-to-head trials comparing with conventional systemic drugs are lacking and large real-world data on the long-term safety profile as compared are scarce.
To compare long-term safety profile of dupilumab with conventional systemic drugs used in the management of moderate to severe AD.
Data from electronic health records of AD patients treated with either dupilumab, azathioprine, Cyclosporine A, mycophenolate mofetil, methotrexate, or oral glucocorticoids were retrieved from the TriNetX
. Risks of adverse events and new onset of type-2-inflammatory diseases within 5 years after treatment initiation was investigated.
5 propensity-matched cohorts, up to 18,708 individuals per cohort, were created. Dupilumab treatment displayed reduced risk for diseases of the circulatory, the upper respiratory, and the musculoskeletal system, infections, and type 2 diseases as compared to all other treatment options. In contrast risk for conjunctivitis was increased in dupilumab treated patients as compared to mycophenolate mofetil and methotrexate.
Here presented data indicates that treatment with dupilumab for AD has reduced risk for adverse effects of conventional systemic drugs and thus might be safer. Obtained data should be verified in prospective studies.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Atopic dermatitis</subject><subject>Azathioprine - adverse effects</subject><subject>Azathioprine - therapeutic use</subject><subject>comorbidities</subject><subject>conventional systemic therapy</subject><subject>Cyclosporine - adverse effects</subject><subject>Cyclosporine - therapeutic use</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Dermatologic Agents - adverse effects</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>dupilumab</subject><subject>Female</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glucocorticoids - adverse effects</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Methotrexate - adverse effects</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Mycophenolic Acid - adverse effects</subject><subject>risk</subject><subject>safety</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>Young Adult</subject><issn>0954-6634</issn><issn>1471-1753</issn><issn>1471-1753</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNo9UU1v1DAQtRCILgs_AeQjl5RxbMcON7Tio1IlDtCz5Y3H1CWJg-1Q7Z_ht-LtbnvxWG_eezOaR8hbBpcMNHyAXoqu4-KyhbY-omWi7Z-RDROKNUxJ_pxsjpzmSLogr3K-A2C8A_2SXPBe6F5CtyH_dnFabAo5zjR6mq3HcqBLij6MSMNMF1sCziXT-1BuqS1xCQN1mKaKl5BpSWgLulPbrUsY18nuaUx0iPPfqgxxtiPNh1xwqtIH_lTxj7T-Rnof0-ios8VSn-JEyy3Smx90xlI7v1-TF96OGd-c65bcfPn8c_etuf7-9Wr36boZOEBpuJaul46BYn0rOAfXA0Ml1CCcZy33XHRKceA9b5kVkqHWyKWSetCsnoRvydXJ10V7Z5YUJpsOJtpgHoCYfhmbShhGNIMTTipe7fcotNQWPKDrOuuVxh5s9Xp_8qpX_LNiLmYKecBxtDPGNRteF9LAVF1mS-SJOqSYc0L_NJqBOcZsHmM2x5jNOeaqe3cese4ndE-qx1z5fy93pFI</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Zirpel, Henner</creator><creator>Ludwig, Ralf J</creator><creator>Olbrich, Henning</creator><creator>Kridin, Khalaf</creator><creator>Ständer, Sascha</creator><creator>Thaçi, Diamant</creator><general>Taylor & Francis Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>202412</creationdate><title>Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network</title><author>Zirpel, Henner ; Ludwig, Ralf J ; Olbrich, Henning ; Kridin, Khalaf ; Ständer, Sascha ; Thaçi, Diamant</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-385d95d1071924330d901e747c4df123f346773039321a451e88e35758c816083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Atopic dermatitis</topic><topic>Azathioprine - adverse effects</topic><topic>Azathioprine - therapeutic use</topic><topic>comorbidities</topic><topic>conventional systemic therapy</topic><topic>Cyclosporine - adverse effects</topic><topic>Cyclosporine - therapeutic use</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Dermatologic Agents - adverse effects</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>dupilumab</topic><topic>Female</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glucocorticoids - adverse effects</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Methotrexate - adverse effects</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Mycophenolic Acid - adverse effects</topic><topic>risk</topic><topic>safety</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zirpel, Henner</creatorcontrib><creatorcontrib>Ludwig, Ralf J</creatorcontrib><creatorcontrib>Olbrich, Henning</creatorcontrib><creatorcontrib>Kridin, Khalaf</creatorcontrib><creatorcontrib>Ständer, Sascha</creatorcontrib><creatorcontrib>Thaçi, Diamant</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>The Journal of dermatological treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zirpel, Henner</au><au>Ludwig, Ralf J</au><au>Olbrich, Henning</au><au>Kridin, Khalaf</au><au>Ständer, Sascha</au><au>Thaçi, Diamant</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network</atitle><jtitle>The Journal of dermatological treatment</jtitle><addtitle>J Dermatolog Treat</addtitle><date>2024-12</date><risdate>2024</risdate><volume>35</volume><issue>1</issue><spage>2421429</spage><pages>2421429-</pages><issn>0954-6634</issn><issn>1471-1753</issn><eissn>1471-1753</eissn><abstract>Safety of dupilumab in atopic dermatitis (AD) was investigated in randomized controlled trials (RCT). However, head-to-head trials comparing with conventional systemic drugs are lacking and large real-world data on the long-term safety profile as compared are scarce.
To compare long-term safety profile of dupilumab with conventional systemic drugs used in the management of moderate to severe AD.
Data from electronic health records of AD patients treated with either dupilumab, azathioprine, Cyclosporine A, mycophenolate mofetil, methotrexate, or oral glucocorticoids were retrieved from the TriNetX
. Risks of adverse events and new onset of type-2-inflammatory diseases within 5 years after treatment initiation was investigated.
5 propensity-matched cohorts, up to 18,708 individuals per cohort, were created. Dupilumab treatment displayed reduced risk for diseases of the circulatory, the upper respiratory, and the musculoskeletal system, infections, and type 2 diseases as compared to all other treatment options. In contrast risk for conjunctivitis was increased in dupilumab treated patients as compared to mycophenolate mofetil and methotrexate.
Here presented data indicates that treatment with dupilumab for AD has reduced risk for adverse effects of conventional systemic drugs and thus might be safer. Obtained data should be verified in prospective studies.</abstract><cop>England</cop><pub>Taylor & Francis Group</pub><pmid>39489506</pmid><doi>10.1080/09546634.2024.2421429</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6634 |
| ispartof | The Journal of dermatological treatment, 2024-12, Vol.35 (1), p.2421429 |
| issn | 0954-6634 1471-1753 1471-1753 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_cd4d5731e7be4858a0f0ed66af78e90a |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Adolescent Adult Antibodies, Monoclonal, Humanized - adverse effects Atopic dermatitis Azathioprine - adverse effects Azathioprine - therapeutic use comorbidities conventional systemic therapy Cyclosporine - adverse effects Cyclosporine - therapeutic use Dermatitis, Atopic - drug therapy Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use dupilumab Female Glucocorticoids - administration & dosage Glucocorticoids - adverse effects Glucocorticoids - therapeutic use Humans Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Male Methotrexate - adverse effects Methotrexate - therapeutic use Middle Aged Mycophenolic Acid - adverse effects risk safety Severity of Illness Index Treatment Outcome United States Young Adult |
| title | Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A31%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20safety%20profile%20in%20patients%20with%20atopic%20dermatitis%20treated%20with%20dupilumab%20or%20conventional%20systemic%20treatment:%20real%20world%20data%20from%20the%20US%20network&rft.jtitle=The%20Journal%20of%20dermatological%20treatment&rft.au=Zirpel,%20Henner&rft.date=2024-12&rft.volume=35&rft.issue=1&rft.spage=2421429&rft.pages=2421429-&rft.issn=0954-6634&rft.eissn=1471-1753&rft_id=info:doi/10.1080/09546634.2024.2421429&rft_dat=%3Cproquest_doaj_%3E3123801739%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c300t-385d95d1071924330d901e747c4df123f346773039321a451e88e35758c816083%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3123801739&rft_id=info:pmid/39489506&rfr_iscdi=true |